Navigation Links
Protein Sciences Corporation Announces Profitable and Cash Flow Positive Results for 2009 and Management Realignment
Date:2/18/2010

MERIDEN, Conn., Feb. 18 /PRNewswire/ -- Protein Sciences Corporation (PSC) announced today that its Board of Directors adopted a succession plan under which Dr. Manon Cox, MBA, currently the Company's Chief Operating Officer, has been elected President and Chief Executive Officer effective March 1, 2010.  Daniel Adams, currently Chairman, President and CEO will then assume the role of Executive Chairman.  

PSC also announced that 2009 was a solidly profitable and cash flow positive year as a result of its contract with BARDA and robust revenues from its GeneXpress® and research antigens businesses.  Revenues (unaudited) grew from $7.6 million to $17.3 million, an increase of 129%, resulting in a pre-tax profit of $3.4 million, a positive cash flow of $1.8 million year end cash and receivables of approximately $3.7 million.  

Daniel Adams, Executive Chairman elect, said, "I could not think of a more capable successor as CEO.  We have been discussing a succession plan for months and everyone concluded that Manon was the right choice to lead the Company at this juncture.  She has done an outstanding job as Chief Operating Officer where she instilled persistence and a growing culture of excellence in the Company and at the same time becoming respected internationally for her expertise in vaccines and influenza."  He added, "I will remain fully active in the Company, focusing primarily on resolving the remaining litigation instituted by Emergent BioSolutions, Inc., securing additional capital through financing and/or strategic partnerships and planning for the future."

Manon Cox, President and CEO elect, said "I am honored that the Board of Directors has chosen me  to succeed Dan Adams who has led this Company with vision to its current position as a profitable, cash flow positive company with a late stage product, FluBlok, our lead recombinant influenza vaccine, that we believe will receive FDA approval later this year."  She added, "PSC is a strong company with a great platform technology for producing modern vaccines such as FluBlok.  FluBlok approval will, we believe, result in our platform technology being used to develop and manufacture whole families of modern recombinant vaccines. Our recent progress to profitability has generated a flood of high level people who want to join our team and can accelerate our growth.  I look forward to bringing them on board."  

About PSC

PSC is a privately held biopharmaceutical company based in Meriden, Connecticut, whose mission it is to save lives and improve health by effectively responding to our changing world with innovative vaccines and biopharmaceuticals.  PSC uses recombinant DNA technology to make novel human and veterinary prophylactic and therapeutic vaccines and diagnostics.  The active ingredients in all of the firm's products are recombinant proteins that are manufactured using its patented protein expression technology based upon baculovirus and insect cell technology.

PSC's lead product is FluBlok, a seasonal recombinant trivalent influenza vaccine consisting of influenza hemagglutin (HA) proteins.  FluBlok is manufactured without the use of eggs, is highly purified and therefore does not require the use of thimerosal or antibiotics, and is low in endotoxins. PSC filed a Biologics License Application for FluBlok with the FDA in April 2008 that was accepted in June 2008 and received "Fast Track" designation in July 2008.  PSC anticipates that FluBlok will receive FDA approval later this year.  PSC was recently awarded a $34.5 million contract from the Biomedical Advanced Research and Development Authority, a division of the Department of Health and Human Services to further develop a new technology, recombinant technology, for the production of recombinant influenza vaccines for pandemic preparedness. This contract could be extended up to five years at a total cost of approximately $147 million.  

SOURCE Protein Sciences Corporation

RELATED LINKS
http://www.proteinsciences.com

'/>"/>

SOURCE Protein Sciences Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Draining away brains toxic protein to stop Alzheimers
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
4. Emory researchers identify signaling protein for multiple myeloma
5. Human C-reactive protein regulates myeloma tumor cell growth and survival
6. Lowering Blood Protein Wont Help Kidney Patients
7. Blood protein detects lung cancer, even at earliest stage
8. Natural Protein Could Help Spot, Treat Liver Cancer
9. Heat shock proteins are co-opted for cancer
10. How adhesive protein causes malaria
11. Loss of gene leads to protein splicing and buildup of toxic proteins in neurons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore Enterprise Cloud, today announced ... to the cloud. Cirracore provides a secure VMware® vCloud Air based cloud ... Transformation Solutions (TSL Partners) provides a full range of services from planning, ...
(Date:2/9/2016)... Springs, FL (PRWEB) , ... February 09, 2016 ... ... leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ ... for each prescription referral received at our specialty pharmacy. , “Since our ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... On January ... family scheduled an appointment after they noticed their furnace not producing any heat. Shortly ... heat exchanger. The cracked heat exchanger was leaking dangerous levels of carbon monoxide into ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: ... stores, announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, ... at the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic ...
(Date:2/9/2016)... ... February 09, 2016 , ... ZipHearing.com is ... to affordable hearing aids , increase industry transparency, and promote awareness of ... States. , “For the average consumer, the hearing aid industry is esoteric and ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Feb. 9, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... editing, today reported its fourth quarter and full ... in vivo therapeutic genome editing," said Edward ... zinc finger nuclease (ZFN) technology leads the therapeutic ... core competencies necessary to move our ground-breaking genome ...
(Date:2/9/2016)... HAMILTON, Bermuda, Feb. 9, 2016  Axovant Sciences ... focused on the treatment of dementia, today announced ... address cognitive, behavioral and functional aspects of Lewy ... people in the U.S. Two out of the ... is expected to start later this quarter. In ...
(Date:2/9/2016)... The new report "Global Diagnostic Ultrasound Devices Market Assessment & Forecast: ... global diagnostic ultrasound devices market was valued at US$ 5,381.1 million ... 2019 at a CAGR of 6.8% from 2015 to 2019. ... analyzed for six geographies of North America , ... Latin America , Middle-East and ...
Breaking Medicine Technology: